Tagged with Strategy,

Switzerland Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits of incremental innovation in anaesthesia, and why having a Swiss headquarters is advantageous.   Up until COVID-19, Anaesthesia was incredibly underrepresented and undervalued as a therapeutic class. However,…

USA Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into rare diseases, product launch strategies, access and affordability issues, and talent attraction challenges.   While it is true you can make great contributions in academia, I think you can make…

Global Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change management that the COVID-19 pandemic has thrown up, why company-HCP interaction might never be the same again, and shares some pearls of wisdom for other women in pharma.   I see Merck’s…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…

USA Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in culture, and the company’s multifaceted response to the COVID-19 crisis.   In general, through the global COVID response, we’ve seen the walls between companies and across sectors come down as…

Switzerland Pfizer Switzerland’s Sabine Bruckner discusses Switzerland’s historic and continuing importance to Pfizer, vaccine development and uptake, and the significant benefits of building a diverse leadership team.   There are challenges and opportunities in every situation and, while there is no doubt that COVID-19 is challenging for all of us, it…

USA Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech success story like Amicus can be a guiding light in market access and pricing discussions.   Ultimately, we envision our…

Norway BMS Norway’s Hilde Bech outlines her hopes of bringing “the medicines of the future” to Norwegian patients, why tiny Norway still has global significance for the company, and offers some pearls of wisdom for the next generation of female leaders.   BMS Norway is absolutely going to be one of…

Switzerland Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning…

Norway Philipp Maerz, the recently appointed head of Merck’s Nordic and Baltic operations and GM for Norway, outlines the challenges of taking on a new management role in the midst of a global pandemic, the innovation-friendliness of the markets under his remit, and his strategy for the cluster.   Culture eats…

Switzerland Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his leadership and talent management philosophy, the investment and commitment Bayer is making towards becoming a global oncology player, as well as his perspectives on digital…

Japan In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven by strong performance in recent years both from the company’s own drugs as well as those of parent company Roche. With Chugai now preparing for Phase III clinical trials for Roche’s Actemra for COVID-19, the company’s share price has…